Robeco Institutional Asset Management B.V. lifted its position in shares of CVS Health Corp (NYSE:CVS) by 3.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 554,451 shares of the pharmacy operator’s stock after purchasing an additional 15,957 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in CVS Health were worth $34,972,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. Executive Wealth Management LLC boosted its holdings in CVS Health by 62.4% in the 2nd quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 217 shares during the period. Manchester Financial Inc. purchased a new position in CVS Health in the 2nd quarter worth approximately $31,000. Hudock Capital Group LLC boosted its holdings in CVS Health by 54.0% in the 2nd quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 202 shares during the period. Tarbox Family Office Inc. boosted its holdings in CVS Health by 74.7% in the 2nd quarter. Tarbox Family Office Inc. now owns 580 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 248 shares during the period. Finally, Gradient Investments LLC boosted its holdings in CVS Health by 78.3% in the 3rd quarter. Gradient Investments LLC now owns 617 shares of the pharmacy operator’s stock worth $39,000 after acquiring an additional 271 shares during the period. Institutional investors and hedge funds own 75.98% of the company’s stock.
CVS Health stock opened at $66.16 on Friday. The stock has a market cap of $86.48 billion, a P/E ratio of 9.34, a price-to-earnings-growth ratio of 1.45 and a beta of 0.86. The company has a current ratio of 0.95, a quick ratio of 0.64 and a debt-to-equity ratio of 1.39. The stock has a 50 day moving average of $62.74 and a 200-day moving average of $57.10. CVS Health Corp has a 52 week low of $51.72 and a 52 week high of $82.15.
CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.70 by $0.19. The company had revenue of $63.43 billion during the quarter, compared to analysts’ expectations of $62.66 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. The business’s revenue was up 35.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.69 EPS. As a group, equities analysts predict that CVS Health Corp will post 6.97 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, November 4th. Investors of record on Thursday, October 24th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend is Wednesday, October 23rd. CVS Health’s dividend payout ratio is currently 28.25%.
A number of equities analysts have weighed in on CVS shares. Evercore ISI set a $63.00 price target on CVS Health and gave the stock a “buy” rating in a report on Wednesday, August 7th. Citigroup upped their price target on CVS Health from $68.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TheStreet upgraded CVS Health from a “c+” rating to a “b-” rating in a report on Monday, September 9th. Deutsche Bank started coverage on CVS Health in a report on Thursday, September 12th. They issued a “buy” rating and a $91.00 price target for the company. Finally, ValuEngine upgraded CVS Health from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $75.39.
In related news, CFO Eva C. Boratto sold 8,130 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $65.00, for a total transaction of $528,450.00. Following the sale, the chief financial officer now directly owns 55,273 shares of the company’s stock, valued at approximately $3,592,745. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Joshua Matthew Flum sold 17,703 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $63.00, for a total value of $1,115,289.00. Following the sale, the executive vice president now directly owns 36,163 shares in the company, valued at $2,278,269. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Further Reading: Momentum Indicators
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.